Eutilex Co Ltd
263050
Company Profile
Business description
Eutilex Co Ltd is a Korean that operates in the anti-tumor immunotherapy market. The company develops anti-tumor T cell therapy and antibody therapeutics based on its immunotherapy technology. Its pipeline products include T Cell Therapy (4-1BB CTL), CAR-T, and Antibody.
Contact
Daeryung Technotown 17
Suite 1401
Gasan Digital 1-ro 25
Geumcheon-gu
Seoul08594
KORT: +82 234027310
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
141
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,813.70 | 100.20 | -1.27% |
| CAC 40 | 7,126.02 | 263.00 | 3.83% |
| DAX 40 | 20,562.73 | 891.85 | 4.53% |
| Dow JONES (US) | 39,593.66 | 1,948.07 | 5.17% |
| FTSE 100 | 7,913.25 | 141.73 | -1.76% |
| HKSE | 20,782.99 | 101.21 | 0.49% |
| NASDAQ | 16,387.31 | 1,119.40 | 7.33% |
| Nikkei 225 | 33,240.21 | 1,368.79 | -3.96% |
| NZX 50 Index | 12,049.14 | 152.29 | -1.25% |
| S&P 500 | 5,268.05 | 188.85 | -3.46% |
| S&P/ASX 200 | 7,607.90 | 101.70 | -1.32% |
| SSE Composite Index | 3,227.65 | 4.02 | 0.12% |